Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Magnesium valproate sustained release tablets (Shentai)

1. Anti epilepsy: it is used to treat generalized or partial epilepsy, especially the following types: absence seizure, myoclonic seizure, tonic clonic seizure, atonic seizure and mixed seizure, and partial epilepsy: simple or complex seizure; Secondary systemic seizures; Special types of syndrome (West, Lennox Gastaut). 2. Anti mania: it is mainly used for the treatment of acute mania, bipolar mania and schizomania. More role
App download minus 10 yuan
Common name:
Magnesium valproate sustained release tablets
Product No.:
B14200069213
Approval No.:
Gyzz h20030537 (inquired by the State Drug Administration)
Jianke price:
¥58.80
Product specification:
0.25g*30s
Manufacturer:
Hunan Xiangzhong Pharmaceutical Co., Ltd
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Magnesium valproate sustained release tablets (Shentai)
Main raw materials The main component of this product is magnesium valproate.
Main role 1. Anti epilepsy: it is used to treat generalized or partial epilepsy, especially the following types: absence seizure, myoclonic seizure, tonic clonic seizure, atonic seizure and mixed seizure, and partial epilepsy: simple or complex seizure; Secondary systemic seizures; Special types of syndrome (West, Lennox Gastaut). 2. Anti mania: it is mainly used for the treatment of acute mania, bipolar mania and schizomania.
Product specification 0.25g*30s
Usage and dosage It is suitable for patients who need 500mg magnesium valproate to control their condition every day: This product is taken orally 250mg each time, twice a day, and gradually added according to the condition and blood concentration according to the doctor's advice. The maximum dose should not be higher than the daily maximum dose of ordinary tablets.
manufacturing enterprise Hunan Xiangzhong Pharmaceutical Co., Ltd
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Magnesium valproate sustained release tablets (Shentai)

[common name] Magnesium valproate sustained release tablets

[specification and model] 0.25g*30s

[manufacturer] Hunan Xiangzhong Pharmaceutical Co., Ltd

[drug type] Western medicine

[approval No.] Gyzz h20030537

[validity period] 36 months

[functional indications] 1. Anti epilepsy: it is used to treat generalized or partial epilepsy, especially the following types: absence seizure, myoclonic seizure, tonic clonic seizure, atonic seizure and mixed seizure, and partial epilepsy: simple or complex seizure; Secondary systemic seizures; Special types of syndrome (West, Lennox Gastaut). 2. Anti mania: it is mainly used for the treatment of acute mania, bipolar mania and schizomania.

[usage and dosage] It is suitable for patients who need 500mg magnesium valproate to control their condition every day: This product is taken orally 250mg each time, twice a day, and gradually added according to the condition and blood concentration according to the doctor's advice. The maximum dose should not be higher than the daily maximum dose of ordinary tablets.

[adverse reactions] 1. Common gastrointestinal disorders (nausea and stomach pain) often occur at the beginning of treatment, but there is no need to stop treatment. The symptoms usually disappear within a few days. 2. Occurrence of abnormal liver function: very few cases have reported serious liver damage or even death. The most high-risk patients (especially those treated with a variety of antiepileptic drugs) are infants with severe seizures and children under the age of 3, especially those with brain damage, mental retardation and / or genetic metabolism or degenerative diseases. After the age of 3, the risk decreases significantly In most cases, liver damage occurred in the first six months of treatment. Suspicious symptoms: clinical symptoms are the basis for early diagnosis, especially before jaundice, the possibility of liver damage should be considered, especially those high-risk patients. a. Nonspecific symptoms, usually sudden, such as fatigue, anorexia, drowsiness, sleepiness, sometimes accompanied by recurrent vomiting and abdominal pain. b. Epilepsy recurrence: patients (or family members of children) should be warned. When the above symptoms occur, they should report to the doctor in time, and immediately carry out clinical examination and liver function examination. Observation: liver function examination should be carried out before treatment and regularly within the first 6 months of treatment, especially for high-risk patients. In general examination, the test reflecting protein synthesis, especially prothrombin rate, is the most relevant. When it is determined that the abnormal low prothrombin rate, especially accompanied by other biochemical abnormalities (obvious reduction of fibrinogen and coagulation factors, increase of bilirubin and transaminase), treatment needs to be stopped. As a preventive measure, if the patient uses salicylate at the same time, it should also be credit, because the metabolic pathway of these drugs is the same. 3. Neurological disorders. During valproic acid treatment, a few patients have drowsiness or numbness and lead to transient coma (encephalopathy). During treatment, they can appear alone or at the same time with epilepsy. When the dose is reduced or stopped, these symptoms will be reduced. These cases are often found after combined treatment, especially with phenobarbital or sudden increase of valproic acid dose. 4. Transient and / or dose-related adverse reactions have been reported: hair loss, mild postural tremor and drowsiness. 5. It has been reported that simple fibrinogen reduction or prolonged bleeding time are usually not accompanied by clinical signs, which mostly occurs at high doses (valproic acid inhibits the second stage of platelet aggregation) 6. Blood system: mostly thrombocytopenia, rare anemia, leucopenia or pancytopenia. 7. Pancreatitis is occasionally reported, sometimes leading to death. 8. Vasculitis is reported 9. Simple and mild hyperammonemia without abnormal liver function occur from time to time, but the treatment does not need to be stopped. 10. Weight gain, amenorrhea and menstrual disorders were also reported. 11. There are occasional reports of reversible or irreversible hearing loss, but a causal relationship is not clear. 12. Valproic acid can cause skin reactions, such as rash. Toxic epithelial necrolysis, Stevens Johnson syndrome and erythema multiforme have also been reported in some cases. 13. There is a separate report of reversible Fanconi syndrome accompanied by valproic acid treatment, but its mechanism is unknown.

[precautions] 1. The side effects of valproic acid often indicate that the plasma valproic acid concentration is greater than 120 μ G / ml, so it is recommended that qualified hospitals should check the blood drug concentration. 2. Pregnant women, patients with liver diseases and patients with thrombocytopenia should be used with caution. Pay attention to symptomatic examination during medication, such as liver function, blood routine, platelet count, etc. 3. In case of serious side effects such as disturbance of consciousness, abnormal liver function and pancreatitis, the drug should be stopped. 4. Avoid drinking alcohol during medication, which can increase the calming effect. 5. Drug withdrawal should be gradually reduced to prevent recurrence. When replacing other anticonvulsant drugs, the dosage of this product should be gradually increased, while the dosage of the substituted drugs should be gradually reduced. 6. For the interference of diagnosis, urine ketone test may be false positive, and thyroid function test may be affected. 7. It can slightly increase lactate dehydrogenase, alanine aminotransferase and aspartate aminotransferase, and suggest asymptomatic liver poisoning. Serum bilirubin may increase, suggesting potential serious liver poisoning. 8. Patients with renal insufficiency should use it with caution. Due to the increased level of free serum valproic acid, it is necessary to reduce the dose of valproic acid. 9. Although it is occasionally reported that immune abnormalities often occur in the application of this product, the benefit and risk of this product need to be weighed when used in patients with systemic lupus erythematosus. 10. Pancreatitis is occasionally reported. Therefore, when the patient has acute abdominal pain, serum amylase should be checked before operation. Please read the instructions carefully and follow the doctor's advice.

[taboo] 1. Leucopenia and severe liver diseases are prohibited. 2. It is forbidden for those allergic to valproic acid drugs. 3. Porphyria is forbidden. 4. Be careful when you have blood disease, history of liver disease, renal function damage and organic encephalopathy.

[listing Permit Holder] Hunan Xiangzhong Pharmaceutical Co., Ltd

[packaging unit] bottle

[main ingredients] The main component of this product is magnesium valproate.

[character] This product is white or off white.

[applicable population] unlimited

[medication for pregnant and lactating women] The risks associated with valproic acid treatment in women with epilepsy during pregnancy are as follows: 1. Risks associated with epilepsy and epilepsy drugs The total incidence of infant malformations born to mothers receiving antiepileptic treatment has been proved to be 2 ~ 3 times higher than that of ordinary pregnant women (3%). Although it has been reported that the infant malformation rate increases when treated with a variety of drugs, the treatment and diseases related to malformations have not been officially determined. The most common malformations are cleft lip and cardiovascular malformation. Sudden interruption of antiepileptic drug treatment may aggravate the mother's condition and cause adverse effects on the fetus. 2. Risks associated with valproic acid In animals, it has been proved that mice, rats and rabbits have teratogenic effects. In humans, the total risk of deformity in women treated with sodium valproate in the first three months of pregnancy is not higher than that of other antiepileptic drugs. Cases of facial deformity have been reported. The incidence of those effects has not been fully determined. Valproic acid has the tendency to cause neural tube defect, spinal meningocele, spina bifida, etc. The incidence of these adverse effects is estimated to be 1-2%. Throughout the above data, if a woman plans to get pregnant, she should review the indications of antiepileptic treatment. Folate supplementation should be considered. During pregnancy, valproic acid antiepileptic treatment should not be stopped if it is effective. It is recommended to use the minimum effective dose every day and take it in several times. If neural tube defects or other malformations are found, special prenatal examination should be carried out. 3. Neonatal risk It has been reported that pregnant mothers use valproic acid and newborns have bleeding syndrome. The bleeding syndrome is related to too little blood fibrin. Low fibrin syndrome has been reported and may be fatal. Hypofibrinoemia may occur with a decrease in coagulation factors. This syndrome should be distinguished from vitamin dependent factor reduction, which is induced by phenobarbital and enzyme inducer. 4. Lactation The secretion of valproic acid in breast milk is low, about 1-10% of the mother's serum level. So far, no clinical side effects have been found in infants breastfed in neonatal period.

[medication for children] This product can be accumulated in developing bones. Children under 6 years old should use it with caution.

[medication for elderly patients] Same as adults. The minimum effective daily dose is recommended.

[storage] Seal and store in a dry place.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Magnesium valproate sustained release tablets (Shentai)

    ¥58.80

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!